Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07188623 · ClinicalTrials.gov registry record · NA

Virtual Reality-Enhanced Behavioral Activation for Older Adults With Depression

A NA study of Depression - Major Depressive Disorder and Older Adults (65 Years and Older), sponsored by Stanford University.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT07188623: Recruiting NA study of Depression - Major Depressive Disorder and Older Adults (65 Years and Older), sponsored by Stanford University.

NCT07188623 is a NA study of Depression - Major Depressive Disorder and Older Adults (65 Years and Older) that is actively recruiting participants, run by Stanford University. The registered enrollment target is 30 participants, below the 101-participant average among 19 other Depression - Major Depressive Disorder trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07188623, a NA study of Depression - Major Depressive Disorder and Older Adults (65 Years and Older), is actively recruiting participants, sponsored by Stanford University.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The primary aims of this study are to assess the feasibility, acceptability, and tolerability of using an immersive virtual reality (VR) headset to engage in behavioral activation (BA) for older adults diagnosed with major depressive disorder (MDD). The secondary aim of this study is to explore the efficacy of using VR to enhance BA therapy in a clinical MDD older adult population.

Primary Outcome

How participants' depression scores on the Geriatric Depression Scale (GDS-15) change over time using VR-enhanced BA. The GDS-15 is a 15-question screener with a score range of 0-15, with 15 indicating the most severe depression and 0 indicating a lack of depression symptoms. The greater the change over time, the greater the symptom reduction.

Interventions

  • BEHAVIORAL VR-Enhanced BA

Study Locations (1)

California

  • Stanford University - Stanford

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2025-09-30
Est. Completion 2026-08
Phase NA
Stanford University

1,744 total trials

What NCT07188623 shows while recruiting

NCT07188623 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 101-participant average among 19 other Depression - Major Depressive Disorder trials with a reported enrollment target (70% lower).

The record links to 4 conditions, with Depression - Major Depressive Disorder appearing as the primary indexed condition, and to 1 intervention - of which VR-Enhanced BA is the first listed.

NCT07188623 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT07188623 about?

NCT07188623 is a clinical study titled "Virtual Reality-Enhanced Behavioral Activation for Older Adults With Depression". The primary aims of this study are to assess the feasibility, acceptability, and tolerability of using an immersive virtual reality (VR) headset to engage in behavioral activation (BA) for older adults diagnosed with major depressive disorder (MDD). The secondary aim of this study is to explore the ...

What is the current status of trial NCT07188623?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2025-09-30. Estimated completion is 2026-08.

What conditions does trial NCT07188623 study?

This clinical trial studies the following conditions: Depression - Major Depressive Disorder, Older Adults (65 Years and Older), Behavioral Activation Treatment, Virtual Reality Therapy.

What interventions are being tested in trial NCT07188623?

The interventions under investigation include: VR-Enhanced BA (BEHAVIORAL).

Who is sponsoring clinical trial NCT07188623?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07188623 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Depression - Major Depressive Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07188623's enrollment target sits among peer trials

30 14th of 19 higher than 3 of 19 other Depression - Major Depressive Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Depression - Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07188623, the US trial registry maintained by the National Library of Medicine. NCT07188623 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.